References
- Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA 2013;310:1842-50
- Ostrom QT, Gittleman H, Farah P, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006–2010. Neuro Oncol 2013;15:ii1-56
- Schwartzbaum JA, Fisher JL, Aldape KD, et al. Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol 2006;2:494-503
- Yuile P, Dent O, Cook R, et al. Survival of glioblastoma patients related to presenting symptoms, brain site and treatment variables. J Clin Neurosci 2006;13:747-51
- Raizer JJ, Fitzner KA, Jacobs DI, et al. Economics of malignant gliomas: a critical review. J Oncol Pract 2014;11:e59-e65
- Ray S, Bonafede MM, Mohile NA. Treatment patterns, survival, and healthcare costs of patients with malignant gliomas in a large US commercially insured population. Am Health Drug Benefits 2014;7:140-9
- Griffiths RI, Gleeson ML, Danese MD, et al. Inverse probability weighted least squares regression in the analysis of time-censored cost data: an evaluation of the approach using SEER-Medicare. Value Health 2012;15:656-63
- Zheng Z, Onukwugha E, Hanna N, et al. Cost-effectiveness of second-line chemotherapy/biologics among elderly metastatic colon cancer patients. Adv Ther 2014;31:724-34
- Basu A, Rathouz PJ. Estimating marginal and incremental effects on health outcomes using flexible link and variance function models. Biostatistics 2005;6:93-109
- Lin D. Linear regression analysis of censored medical costs. Biostatistics 2000;1:35-47
- Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96
- Stupp R, Taillibert S, Kanner AA, et al. Maintenance therapy with tumor-treating fields plus Temozolomide vs Temozolomide alone for glioblastoma: a randomized clinical trial. JAMA 2015;314:2535-43
- Bernard-Arnoux F, Lamure M, Ducray F, et al. The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma. Neuro Oncol 2016;18:1129-36
- Henaine A, Paubel N, Ducray F, et al. Current trends in the management of glioblastoma in a French University Hospital and associated direct costs. J Clin Pharm Ther 2016;41:47-53
- Lamers LM, Stupp R, van den Bent MJ, et al. Cost‐effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme. Cancer 2008;112:1337-44
- Uyl-de Groot CA, Stupp R, Bent Mvd. Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme. Expert Rev Pharmacoecon Outcomes Res 2009;9:235-41
- Campion FX, Larson LR, Kadlubek PJ, et al. Advancing performance measurement in oncology: quality oncology practice initiative participation and quality outcomes. J Oncol Pract 2011;7:31s-5s
- Newcomer LN, Gould B, Page RD, et al. Changing physician incentives for affordable, quality cancer care: results of an episode payment model. J Oncol Pract 2014;10:322-6
- Schnipper LE, Davidson NE, Wollins DS, et al. Updating the American Society of Clinical Oncology value framework: revisions and reflections in response to comments received. J Oncol Pract 2016;34:2925-34